Effectiveness of aprepitant in post-acute COVID19 syndrome

Rocío Reinoso-Arija; Cecilia López-Ramírez; José Antonio Jimenez-Ruiz; José Luis López-Campos

doi:10.1002/ccr3.4646

Effectiveness of aprepitant in post-acute COVID19 syndrome

Clin Case Rep. 2021 Sep 18;9(9):e04646. doi: 10.1002/ccr3.4646. eCollection 2021 Sep.

Authors

Rocío Reinoso-Arija¹, Cecilia López-Ramírez¹, José Antonio Jimenez-Ruiz², José Luis López-Campos^{1

3}

Affiliations

¹ Unidad Médico-Quirúrgica de Enfermedades Respiratorias Instituto de Biomedicina de Sevilla (IBiS) Hospital Universitario Virgen del Rocío/Universidad de Sevilla Sevilla Spain.
² Research Group on Electronic Technology and Industrial Computing (TIC-150) University of Sevilla Sevilla Spain.
³ Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES) Instituto de Salud Carlos III Madrid Spain.

Abstract

This is the first case of a patient taking aprepitant for a post-acute COVID-19 syndrome. This case may encourage researchers to look for the evidence for the efficacy and safety of a neurokinin 1 receptor antagonist in this frequent syndrome.

Keywords: COVID19; SARS‐CoV‐2; aprepitant; post‐acute.

Publication types

Case Reports